Abstract 153P
Background
Long non-coding RNAs (LncRNAs) widely involved in various processes in cancers. Exosomes are important elements in tumor microenvironment, and usually transmit miRNAs or LncRNAs in cancer cells. Rapid progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation has been confirmed, however, the role of exosomes in the underlying mechanism has never been unmasked.
Methods
The expression of LINC00174 was modified in the Huh7 and Huh7-H cell lines respectively. Western blot was used to examine the level of the exosomal protein marker. Transwell assay and western blot were used to evaluate the migration function of the HCC cells. qRT-PCR and western blot were used to examine the expression of LINC00174 level in the exosomes derived from the modified HCC cells. Online UCSC and JASPAR were used to predict the LINC00174 transcription. ChIP and a luciferase reporter assay were used to validate the positive regulation of MYC on LINC00174 transcription.
Results
LINC00174 was upregulated in both the cells and exosomes of cells. LINC00174 affected HCC cell migration and EMT via ERK and JNK pathways. The changes of c-JUN and p-c-JUN level in HCC cells treated with exosomes containing different level of LINC00174. JASPAR revealed the binding motif of c-JUN protein on the promoter region of its targets. ChIP and luciferase reporter assay validated that c-JUN was a positive regulator of MYCBP transcription. Exosomal LINC00174 activated Ras-regulated ERK and JNK pathways to enhance c-JUN expression and phosphorylation, and therefore upregulated MYCBP to strengthen MYC transcriptional activity, finally resulting in accelerated HCC progression.
Conclusions
Exosomal LINC00174 facilitates EMT via ERK-JNK/c-JUN/MYCBP/c-MYC signaling, providing a new way for the HCC patients unfortunately received the insufficient RFA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhe jiang Cancer Hospital.
Funding
National Natural Science Funds of China (Grant number: 81702371).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract